Axumin (fluciclovine f18) is a small molecule pharmaceutical. Fluciclovine f18 was first approved as Axumin on 2016-05-27. It has been approved in Europe to treat prostatic neoplasms and radionuclide imaging. Axumin's patents are valid until 2035-12-30 (FDA).
|Common Name||Fluciclovine (18f)|
|Indication||prostatic neoplasms, radionuclide imaging|
|Drug Class||Vinca alkaloids|